Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

111 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

dbGaP phs000600 Genomic Sequencing of Cervical Cancers - Eligibility

- 09.01.23 - 5 Formulare, 1 Itemgruppe, 1 Datenelement, 1 Sprache
Itemgruppe: IG.elig
Principal Investigator: Matthew Meyerson, MD,PhD, Dana Farber Cancer Institute, Boston MA, USA MeSH: Uterine Cervical Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000600 Cervical cancer is responsible for 10-15% of cancer related deaths in women worldwide. The etiological role of infection with high-risk human papilloma viruses (HPV) in carcinomas of the cervix is well established. In general, the development of cervical carcinomas follows a progression from persistent HPV infection through precancerous lesions to invasive cancer. Previous studies have implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS as well as chromosome-arm level copy number alterations in the pathogenesis of cervical carcinomas. Here, we report whole exome sequencing analysis of 118 cervical carcinoma-normal paired samples from patients in Norway and Mexico, as well as transcriptome sequencing of 80 cases and whole genome sequencing of 13 tumor-normal pairs. Novel somatic mutations include recurrent E322K substitutions in the MAPK1 gene encoding the ERK2 kinase and inactivating mutations in the HLA-B gene. In addition, recurrent somatic mutations in FBXW7, EP300, and NFE2L2 are novel in the context of primary cervical carcinomas. Analysis of HPV integration sites revealed recurrent integration into the RAD51B locus as well as co-occurrence of HPV genome integration and copy number gains within several genomic loci. These findings shed new light on the pathogenesis of cervical carcinomas and suggest potential novel therapeutic targets.

pht003237.v1.p1

1 Itemgruppe 5 Datenelemente

pht003238.v1.p1

1 Itemgruppe 5 Datenelemente

pht003239.v1.p1

1 Itemgruppe 6 Datenelemente

pht003240.v1.p1

1 Itemgruppe 8 Datenelemente

dbGaP phs000723 Sequencing of Cervical Cancer - Eligibility

- 06.01.23 - 5 Formulare, 1 Itemgruppe, 1 Datenelement, 1 Sprache
Itemgruppe: IG.elig
Principal Investigator: Yick Fu Wong, Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA MeSH: Uterine Cervical Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000723 Precision mapping of genetic alterations in cancer can enable better selection of therapies and improved outcomes when combined with new sequencing diagnostics. We describe whole-exome sequences from cervical adenocarcinomas and paired normal samples in Hong Kong Chinese women. These data uncover a heterogeneous genomic landscape but identify commonly aberrant loci including FAT1, ARID1A, ERBB2 and PIK3CA that may provide a focus for the development of individualized targeted therapies for Chinese women with cervical adenocarcinoma.

pht005210.v1.p1

1 Itemgruppe 5 Datenelemente

pht005211.v1.p1

1 Itemgruppe 5 Datenelemente

pht005212.v1.p1

1 Itemgruppe 7 Datenelemente

pht005213.v1.p1

1 Itemgruppe 12 Datenelemente

dbGaP phs000628 Characterization of a Metastatic Cervical Cancer Using NGS - pht003504.v1.p1

- 29.11.22 - 4 Formulare, 1 Itemgruppe, 3 Datenelemente, 1 Sprache
Itemgruppe: pht003504
Principal Investigator: Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA MeSH: Uterine Cervical Neoplasms,Carcinoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000628 In this study, we used shallow whole genome, exome, and RNA sequencing to genomically and transcriptomically characterize a cervical squamous carcinoma lesion metastatic to the lung and to detect and analyze HPV infection in the same sample.

pht003505.v1.p1

1 Itemgruppe 3 Datenelemente

pht003506.v1.p1

1 Itemgruppe 4 Datenelemente

pht003507.v1.p1

1 Itemgruppe 6 Datenelemente

dbGaP phs000640 HeLa Cell Genome Sequencing Studies - pht006074.v1.p1

- 25.11.22 - 18 Formulare, 1 Itemgruppe, 12 Datenelemente, 1 Sprache
Itemgruppe: pht006074
Principal Investigator: MeSH: Uterine Cervical Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000640 This study contains all authorized whole genome sequence data of the HeLa cell line from datasets currently in dbGaP. These data have been approved for health, medical, and/or biomedical research purposes. Access to these data can be granted for one year. Accessible data will include the studies listed on this page and any additional authorized datasets that become available during this one-year period. The HeLa Genome Data Access Working Group of the Advisory Committee to the Director (ACD) will review requests from the research community for access to these datasets and assess whether the requests align with the terms of use defined in the HeLa Genome Data Use Agreement. The Working Group's findings will be reported to the ACD, and the ACD will make recommendations to the NIH Director about whether a request should be approved or disapproved. The NIH Director will decide whether access to the data will be granted.

pht006081.v1.p1

1 Itemgruppe 12 Datenelemente

pht003440.v3.p1

1 Itemgruppe 3 Datenelemente

pht003441.v3.p1

1 Itemgruppe 3 Datenelemente

pht003611.v1.p1

1 Itemgruppe 4 Datenelemente

pht003613.v1.p1

1 Itemgruppe 6 Datenelemente

pht005078.v1.p1

1 Itemgruppe 7 Datenelemente

Cervical Cancer Registration SWOG S0227 NCT00057928 - Registration Form Cervical Cancer NCT00057928

- 27.09.21 - 1 Formular, 2 Itemgruppen, 29 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient data
Southwest Oncology Group Registration Form (S0227) S0227 Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer NCT00057928 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A9C4563A-B1F7-3ACF-E034-0003BA12F5E7

Cervical Cancer Radiation with or without Chemotherapy NCT01101451 GOG-0263 - Lab and Specimen (Form SP)

- 20.09.21 - 1 Formular, 5 Itemgruppen, 50 Datenelemente, 1 Sprache
Itemgruppen: HEADER MODULE, SPECIMEN INFORMATION, BLOOD/FLUID PRODUCTS, TISSUE/CELLS, GOG TISSUE BANK/LABORATORY INFORMATION
Lab - Gynecologic Oncology Group Specimen Form (Form SP) - 2759412v1.0 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery https://clinicaltrials.gov/ct2/show/NCT01101451

RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Initial Evaluation Form (I1) NCT00980954

- 20.09.21 - 1 Formular, 8 Itemgruppen, 79 Datenelemente, 1 Sprache
Itemgruppen: Header Module, Assessment, Histologic Category, HIGH RISK FEATURES, Examinations, Baseline Lab Values, General Conditions, Footer Module
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Initial Evaluation Form (I1) NCT00980954 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5D016EA3-A43F-2E2A-E044-0003BA3F9857

NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Concurrent Systemic Treatment Summary Form (TF)

- 20.09.21 - 1 Formular, 6 Itemgruppen, 59 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Summary of Systemic Treatment, Treatment Summary, Protocol Specific Adverse Event Evaluation, Lab results, Footer Module
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Concurrent Systemic Treatment Summary Form (TF) Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5FE95381-CD25-390D-E040-BB89AD436907

NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Adjuvant System Treatment Summary Form (SF)

- 20.09.21 - 1 Formular, 6 Itemgruppen, 61 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Lab results, Comments
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Adjuvant System Treatment Summary Form (SF) Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5CFDEE98-0544-2FA7-E044-0003BA3F9857

NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form

- 20.09.21 - 1 Formular, 5 Itemgruppen, 38 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Death Assessment, Has Patient Been Diagnosed With A New Progression?, Non-Protocol Therapy, Adverse Events
NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5C78147E-D46C-4734-E044-0003BA3F9857

GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix) NCT00803062

- 20.09.21 - 1 Formular, 4 Itemgruppen, 84 Datenelemente, 1 Sprache
Itemgruppen: Patient demographics, Miscellaneous Patient Information, Lab Results, Provide comments about this Fast Fact Sheet
GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix) NCT00803062 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=79B3F748-B0A4-3597-E040-BB89AD433B56

Cervical Cancer NCT00262821 Lab - Specimen Form, Form SP, GOG-0219 - 2302462v3.0 - Specimen Form, Form SP, GOG-0219

- 17.09.21 - 1 Formular, 7 Itemgruppen, 55 Datenelemente, 1 Sprache
Itemgruppen: HEADER MODULE, SITE CONTACT INFORMATION, GENERAL SPECIMEN INFORMATION, BLOOD/FLUID PRODUCTS, TISSUE/CELLS, GOG TISSUE BANK/LABORATORY INFORMATION, FOOTER MODULE
Specimen Form, Form SP, GOG-0219 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EF898F9F-93F3-0C07-E034-0003BA3F9857

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video